Search results
United Therapeutics (NASDAQ:UTHR) sheds 5.3% this week, as yearly returns fall more in line with...
Simply Wall St. via Yahoo Finance· 10 months agoBy buying an index fund, investors can approximate the average market return. But if you buy good...
Why United Therapeutics (UTHR) Might Surprise This Earnings Season
Zacks via Yahoo Finance· 3 months agoInvestors are always looking for stocks that are poised to beat at earnings season and United...
United Therapeutics (NASDAQ:UTHR) rises 3.4% this week, taking three-year gains to 178%
Simply Wall St. via Yahoo Finance· 2 years agoIt might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its...
Biotech/Drug Stocks' Q1 Earnings Due May 3: UTHR, PCRX & More
Zacks via Yahoo Finance· 1 year agoQuite a few pharma and biotech bigwigs reported results last week, with the earnings picture looking...
Investors in United Therapeutics (NASDAQ:UTHR) have seen stellar returns of 143% over the past five...
Simply Wall St. via Yahoo Finance· 5 months agoWhen you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and...
United Therapeutics (UTHR) Gains on Tyvaso DPI Approval
Zacks via Yahoo Finance· 2 years agoThe FDA approves United Therapeutics' (UTHR) drug-device combination therapy, Tyvaso DPI, for PAH...
United Therapeutics (UTHR) Q4 Earnings & Sales Miss Estimates
Zacks via Yahoo Finance· 1 year agoUnited Therapeutics‘ UTHR fourth-quarter 2022 adjusted earnings of $2.67 per share missed the Zacks...
United Therapeutics (UTHR) Initiates Tyvaso Study in IPF
Zacks via Yahoo Finance· 2 years agoUnited Therapeutics (UTHR) initiates a second phase III study evaluating its Tyvaso inhalation...
United Therapeutics (UTHR) Q1 Earnings Top, Tyvaso Drives Sales
Zacks via Yahoo Finance· 3 weeks agoUnited Therapeutics‘ UTHR first-quarter 2024 earnings of $6.17 per share beat the Zacks Consensus...
United Therapeutics (UTHR) Q2 Earnings Miss Estimates, Revenues Up
Zacks via Yahoo Finance· 2 years agoUnited Therapeutics' (UTHR) second-quarter earnings missed estimates, while sales beat the same....